BIOGEN HIRLULOG LOWER INCIDENCE OF BLEEDING COMPLICATIONS v. HEPARIN IS DEEMED INSUFFICIENT CLINICAL RESULT; FIRM REDEPLOYING RESOURCES TO BETA INTERFERON

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".